CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← SINOVAC BIOTECH LTD (SVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

SINOVAC BIOTECH LTD (SVA)

Pharmaceutical Preparations · market cap $465M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-01-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Sinovac Biotech (SVA) is a vaccine developer with a market cap of about $465M (~$6.47/share). Our data lists dozens of programs, most in Phase 2/3, across polio, hepatitis A, enterovirus 71/HFMD, influenza, pneumococcal, varicella, mumps, herpes zoster, rotavirus, tetanus and COVID-19. Revenue has fallen from $19.4B in 2021 to $386M in 2025, and the company swung to a $199M net loss last year.
The catalyst path
  • 2027-01-15 (est.)Phase 3 · Experimental vaccineimp 9/10
  • 2027-04-15 (est.)Phase 3 · Experimental vaccineimp 9/10
  • 2027-09-15 (est.)Phase 3 · Inactivated Hepatitis A Vaccine (Human Diploid Cell)imp 9/10
Pipeline
AssetPhaseIndication
Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderlyPhase 3Covid19
PROVARIXPhase 3Varicella (Chickenpox)
36-71 months old children-experimental EV71 vaccinePhase 3Hand, Foot and Mouth Disease
investigational 23-valent PPVPhase 3Pneumococcal Infections
Investigational sIPVPhase 3Poliomyelitis
EV71 vaccinePhase 3Hand, Foot and Mouth Disease
three consecutive lots of EV71 vaccinePhase 3Hand, Foot and Mouth Disease
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of agePhase 3Poliomyelitis
Quadrivalent influenza vaccinePhase 3Seasonal Influenza
Single-dose regimen of high dosage investigational sIPVPhase 2Poliomyelitis
sIPV-sIPV-bOPV vaccination schedulePhase 3Poliomyelitis
Trivalent influenza vaccine (contains B/Victoria strain)Phase 3Seasonal Influenza
pandemic influenza vaccine (H5N1 strain NIBRG-14)Phase 2Pandemic Influenza
EV71 vaccine with adjuvantPhase 2Infection, Viral, Enterovirus
sIPV-bOPV-bOPV vaccination schedulePhase 3Poliomyelitis
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)Phase 2Influenza
Influenza Vaccine (Split Virion), Inactivated, QuadrivalentPhase 3Seasonal Influenza
Experimental vaccinePhase 3Poliomyelitis
bivalent enterovirus vaccine (Vero cell), inactivatedPhase 3Hand, Foot, and Mouth Disease(HFMD)
Sabin Strain Inactivated Poliovirus VaccinePhase 3Poliomyelitis
Price & technical context
3-month
+0.0%
6-month
+0.0%
12-month
+0.0%
52-wk range
$6.47–$6.47
vs 50-day MA
-0.0%
vs 200-day MA
-0.0%
Realized vol
0.0%
Max drawdown
0.0%

Daily closes through 2026-10-28. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SVA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.